2. Search Result
Search Result
Results for "

acidification

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

2

Biochemical Assay Reagents

29

Peptides

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108462
    ML-SA1
    3 Publications Verification

    		 Dengue virus TRP Channel Flavivirus Infection
    ML-SA1, as a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral .
    ML-SA1
  • HY-D0166
    Neutral Red

    		Fluorescent Dye Others
    Neutral Red, a nitrogenous pH-indicator with a pKi of 6.8, is an indicator for the internal acidification of thylakoids. Neutral Red stains lysosomes red .
    Neutral Red
  • HY-N1724
    Concanamycin A
    10+ Cited Publications

    Antibiotic X 4357B; Folimycin; X 4357B

    		 Proton Pump Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H +-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research - .
    Concanamycin A
  • HY-122077
    NS5818

    		Chloride Channel Metabolic Disease
    NS5818 is a potent chloride channel inhibitor. NS5818 inhibits acidification and bone resorption. NS5818 has the potential for the research of osteoporosis .
    NS5818
  • HY-N8530
    Conodurine

    		Others Inflammation/Immunology
    Conodurine is a monoterpenoid indole alkaloid. Conodurine can inhibit lysosomal acidification. Conodurineis isolated from the natural Tabernaemontana corymbosa .
    Conodurine
  • HY-169210
    ECDD-S18

    		Apoptosis Cancer
    ECDD-S18 (compund ECDD-S18) induces apoptosis in a dose-dependent manner, effectively targets vacuolar ATPase (V-ATPase), and impairs lysosomal acidification .
    ECDD-S18
  • HY-W010162
    H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala)

    L-Alanyl-L-alanine; Ala-Ala

    		 Amino Acid Derivatives Others
    H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala) is a nonpolar dipeptide that is absorbed by human intestinal Caco-2 cells. The transport of alanine (Ala), like proton/amino acid symport, can lead to cytoplasmic acidification .
    H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala)
  • HY-168122
    Apoptosis inducer 29

    		Apoptosis Cancer
    Apoptosis inducer 29 (compund Y9) is an apoptosis inducer that exhibits antitumor effects in non-small cell lung cancer. Apoptosis inducer 29 selectively acidifies lysosomes and induces lysosomal dysfunction, with superior potency to Gboixn (HY-111651) in vitro and in vivo. .
    Apoptosis inducer 29
  • HY-125540
    Saussureamine C

    		Influenza Virus Infection Inflammation/Immunology
    Saussureamine C shows gastroprotective effect on acidified ethanol-induced gastric mucosal lesions in rats. Saussureamine C inhibits H274Y and N294S mutants and can be used for research of influenza virus infection. Saussureamine C can be isolated from the dried roots of Saussurea lappa Clarke .
    Saussureamine C
  • HY-D1560
    FG 488 DHPE

    		Fluorescent Dye Others
    FG 488 DHPE is a lipid-coupled fluorochrome, has be used as a fluorophore Oregon Green 488. FG 488 DHPE monitors acidification of lipid vesicles with λex/λem=508/534 nm.FG 488 DHPE is also used for Hv1-induced proton translocation quantificatio with λex/λem=508/534 nm as well .
    FG 488 DHPE
  • HY-100558
    Bafilomycin A1
    Maximum Cited Publications
    465 Publications Verification

    BafA1

    		 Proton Pump Autophagy Antibiotic Bacterial Apoptosis Infection Cancer
    Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H +-ATPase (V-ATPase) with IC50 values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis .
    Bafilomycin A1
  • HY-138896
    (9E,11E)-9-Nitro-9,11-octadecadienoic acid

    9E,11E-9-Nitro CLA

    		 Others Others
    (9E,11E)-9-Nitro-9,11-octadecadienoic acid (9E,11E-9-Nitro CLA) is a nitro-fatty acid, It is formed by exposure of 9Z, 11E-CLA to acidified nitrite, peroxynitrite, gaseous nitrogen dioxide, or a combination of myeloperoxidase, hydrogen peroxide, and nitrite .
    (9E,11E)-9-Nitro-9,11-octadecadienoic acid
  • HY-N2532
    Diphyllin

    		VSV HIV Proton Pump Influenza Virus Infection Inflammation/Immunology Cancer
    Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent HIV-1 inhibitor with an IC50 of 0.38 μM. Diphyllin is active against vesicular stomatitis virus (VSV) and influenza virus . Diphyllin is a vacuolar type H +-ATPase (V-ATPase) inhibitor with an IC50 value of 17 nM and inhibits lysosomal acidification in human osteoclasts . Diphyllin inhibits NO production with an IC50 of 50 μM and has anticancer and anti-inflammatory activities .
    Diphyllin
  • HY-P2090
    Angiopeptin

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
    Angiopeptin
  • HY-119497
    SB251023

    		Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    SB251023 is a β3-adrenergic receptor agonist with pEC50 values of 7.14 and 6.91 for the β3a- and β3b-adrenergic receptors, respectively. SB251023 is capable of modulating cyclic AMP levels and extracellular acidification rate (EAR) in cells. It has potential application value in the study of cardiovascular diseases and metabolic-related disorders .
    SB251023
  • HY-P2090A
    Angiopeptin TFA

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
    Angiopeptin TFA
  • HY-P5894
    human GALP (3-32)

    Galanin-like peptide (3-32)

    		 Neuropeptide Y Receptor Neurological Disease
    human GALP (3-32) (Galanin-like peptide (3-32)) is a potent galanin receptor agonist with high affinity for both GalR1 (IC50=33 nM) and GalR2 (IC50=15 nM) in a competitive binding study. human GALP (3-32) exhibits the high potency in altering the extracellular acidification rate of SH-SY5Y cells transfected with GalR2 (EC50=360 nM) .
    human GALP (3-32)
  • HY-W010162R
    H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala) (Standard)

    		Amino Acid Derivatives Others
    H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala) (Standard) is the analytical standard of H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala). This product is intended for research and analytical applications. H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala) is a nonpolar dipeptide that is absorbed by human intestinal Caco-2 cells. The transport of alanine (Ala), like proton/amino acid symport, can lead to cytoplasmic acidification .
    H-Ala-Ala-OH (L-Alanyl-L-alanine; Ala-Ala) (Standard)
  • HY-P10218
    MANS peptide

    		MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide
  • HY-P10218A
    MANS peptide TFA

    		MARCKS PKC Inflammation/Immunology Cancer
    MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
    MANS peptide TFA
  • HY-128892
    EN6
    3 Publications Verification

    		 Autophagy Neurological Disease
    EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
    EN6
  • HY-151406
    hCAIX-IN-13

    		Apoptosis Cancer
    hCAIX-IN-13 (Pt2) is an inhibitor of CAIX (arbonic anhydrase IX) with an IC50 value of 6.57 μM. hCAIX-IN-13 inhibits growth of cancer cells and induces cell apoptosis, it can be used for the research of cancer .
    hCAIX-IN-13
  • HY-100206
    5α-Androstane-3β,5,6β-triol

    		AMPK Neurological Disease
    5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo .
    5α-Androstane-3β,5,6β-triol
  • HY-P10318
    SHR-2042

    		GLP Receptor Endocrinology
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
    SHR-2042
  • HY-P10200
    CP7-FP13-2

    		Bacterial Infection
    CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
    CP7-FP13-2
  • HY-P0041
    F992

    		Vasopressin Receptor Neurological Disease
    F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992
  • HY-P0041A
    F992 TFA

    		Vasopressin Receptor Neurological Disease
    F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .
    F992 TFA
  • HY-P3462
    Cagrilintide

    		CGRP Receptor Metabolic Disease
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
    Cagrilintide
  • HY-P3462A
    Cagrilintide acetate

    		CGRP Receptor Metabolic Disease
    Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
    Cagrilintide acetate
  • HY-P5161A
    FC382K10W15 TFA

    		GCGR Metabolic Disease
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
    FC382K10W15 TFA
  • HY-P10271
    RG7697

    		GLP Receptor Metabolic Disease
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
    RG7697
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-P3143
    BMSpep-57

    		PD-1/PD-L1 Cancer
    BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50?of 7.68?nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57
  • HY-P3143A
    BMSpep-57 hydrochloride

    		PD-1/PD-L1 Cancer
    BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57 hydrochloride
  • HY-113560
    Plipastatin B1

    		Antibiotic Fungal Phospholipase Infection
    Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A2 (PLA2), which has antifungal activity .
    Plipastatin B1
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-P1162
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

    SKF 100273

    		 Vasopressin Receptor Metabolic Disease
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .
    (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
  • HY-P10031
    SAR441255

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
    SAR441255
  • HY-P10031A
    SAR441255 TFA

    		GLP Receptor GCGR Metabolic Disease
    SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors. SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
    SAR441255 TFA
  • HY-P10272
    Rusfertide

    PTG-300

    		 Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
    Rusfertide
  • HY-P4895
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin

    		Oxytocin Receptor Neurological Disease
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-P10563
    Noraramtide

    BHV-1100

    		 CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: